Evidence map›Paper›PMID 28298456›Full record

ArticleThe Journal of experimental medicine2017

Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity.

Eva Czirr, Nicholas A Castello, Kira I Mosher, Joseph M Castellano, Izumi V Hinkson, Kurt M Lucin, Bernat Baeza-Raja, Jae Kyu Ryu, Lulin Li, Sasha N Farina and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 136 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Experimental modeling of Alzheimer's disease: Translational lessons from cross-taxon analyses.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  8. Cathepsin B modulates microglial migration and phagocytosis of amyloid β in Alzheimer's disease through PI3K-Akt signaling.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Eva CzirrDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0003-0247-0631
Nicholas A CastelloGladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158.
Kira I MosherDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Joseph M CastellanoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0002-8026-6292
Izumi V HinksonDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Kurt M LucinDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Bernat Baeza-RajaGladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158.ORCID 0000-0003-4458-3079
Jae Kyu RyuGladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158.ORCID 0000-0002-3992-4011
Lulin LiDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Sasha N FarinaDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Nadia P BelichenkoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Frank M LongoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Katerina AkassoglouGladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158.ORCID 0000-0002-2632-1465
Markus BritschgiDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
John R CirritoDepartment of Neurology, Washington University, St. Louis, MO 63110.
Tony Wyss-CorayDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305 twc@Stanford.edu.ORCID 0000-0001-5893-0831
Stanford University · USGladstone Institutes · USVA Palo Alto Health Care System · USWashington University in St. Louis · US

Funding

Viral Vectors CoreP01NS074969 · NINDS · WASHINGTON UNIVERSITY · PI SNIDER, BARBARA JOY · 2012 to 2021
$13.0M
Neurovascular Interactions: Mechanisms, imaging, therapeutic potentialR35NS097976 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI AKASSOGLOU, KATERINA · 2016 to 2023
$11.1M
Working Memory in Parkinson Disease: A Cognitive & Systems Neuroscience ApproachP50AG047366 · NIA · STANFORD UNIVERSITY · PI HENDERSON, VICTOR · 2015 to 2019
$7.9M
SYNAPTIC REGULATION OF ERK-MEDIATED AMYLOID-BETA METABOLISMR01AG042513 · NIA · WASHINGTON UNIVERSITY · PI CIRRITO, JOHN R · 2012 to 2016
$1.5M
Circulatory Rejuvenating Factors for the BrainR01AG045034 · NIA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI WYSS-CORAY, TONY · 2013 to 2017
$1.4M
NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG042513NIA NIH HHS R01 AG045034NINDS NIH HHS P01 NS074969NINDS NIH HHS R35 NS097976
6 · The paper itself

Abstract

Recent genetic evidence supports a link between microglia and the complement system in Alzheimer's disease (AD). In this study, we uncovered a novel role for the microglial complement receptor 3 (CR3) in the regulation of soluble β-amyloid (Aβ) clearance independent of phagocytosis. Unexpectedly, ablation of CR3 in human amyloid precursor protein-transgenic mice results in decreased, rather than increased, Aβ accumulation. In line with these findings, cultured microglia lacking CR3 are more efficient than wild-type cells at degrading extracellular Aβ by secreting enzymatic factors, including tissue plasminogen activator. Furthermore, a small molecule modulator of CR3 reduces soluble Aβ levels and Aβ half-life in brain interstitial fluid (ISF), as measured by in vivo microdialysis. These results suggest that CR3 limits Aβ clearance from the ISF, illustrating a novel role for CR3 and microglia in brain Aβ metabolism and defining a potential new therapeutic target in AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBenzoatesBrainMacrophage-1 AntigenMiceMice, Inbred C57BLMicrogliaProteolysisThiohydantoinsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBenzoatesleukadherin-1Macrophage-1 AntigenThiohydantoins

Identifiers

PMID28298456
PMCPMC5379986
OpenAlexW2596986005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.